

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized, Double-Blind, Phase 3, Noninferiority Equivalence Trial

BioDrugs

35, 337-350

DOI: [10.1007/s40259-021-00475-w](https://doi.org/10.1007/s40259-021-00475-w)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer. <i>Cancers</i> , 2021, 13, 2922.	1.7	29
2	Biosimilars in an era of rising oncology treatment options. <i>Future Oncology</i> , 2021, 17, 3881-3892.	1.1	5
3	Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer. <i>JAMA Oncology</i> , 2022, 8, 537.	3.4	11
4	Trastuzumab, Pyrotinib and Paclitaxel for HER2-positive breast cancer after multiline targeted therapies. <i>Minerva Medica</i> , 2022, , .	0.3	0
5	A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-14010 versus Reference Trastuzumab. <i>Current Oncology</i> , 2022, 29, 4224-4234.	0.9	5
6	Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis. <i>Immunopharmacology and Immunotoxicology</i> , 0, , 1-7.	1.1	2
7	Biosimilar monoclonal antibodies in China: A patent review. <i>Bioengineered</i> , 2022, 13, 14503-14518.	1.4	3
8	Elimination of infusion-related reactions after the switch of Herceptin® with. <i>Minerva Medica</i> , 0, , .	0.3	0
9	Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. <i>Biomedicines</i> , 2022, 10, 2045.	1.4	11
10	Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 0, , 1-10.	0.7	0
11	Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China. <i>Clinical Drug Investigation</i> , 2022, 42, 937-947.	1.1	3
12	Evaluating the efficacy and microenvironment changes of HER2+ gastric cancer during HLX02 and Endostar treatment using quantitative MRI. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
13	Effectiveness and Safety of Zercepac and Reference Trastuzumab in the Neoadjuvant Setting for Early-Stage Breast Cancer: A Retrospective Cohort Study. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	1
14	Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis. <i>BioDrugs</i> , 2023, 37, 205-218.	2.2	0
15	Comparing the pharmacokinetics, safety, and immunogenicity of HLX02 to US- and EU-approved trastuzumab in healthy Chinese male subjects: A Phase I, randomized, double-blind, parallel-group study. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 717-725.	1.4	0
16	Biosimilars: navigating the regulatory maze across two worlds. <i>Trends in Biotechnology</i> , 2023, , .	4.9	0